Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $217,954 | 116 | 97.0% |
| Food and Beverage | $4,284 | 209 | 1.9% |
| Travel and Lodging | $2,517 | 11 | 1.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., Inc. | $220,610 | 132 | $0 (2024) |
| Novo Nordisk Inc | $643.17 | 35 | $0 (2024) |
| Lilly USA, LLC | $405.03 | 24 | $0 (2024) |
| Amgen Inc. | $367.19 | 13 | $0 (2024) |
| ABBVIE INC. | $362.46 | 16 | $0 (2024) |
| PFIZER INC. | $347.09 | 18 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $198.36 | 8 | $0 (2018) |
| Medtronic, Inc. | $175.34 | 3 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $172.06 | 9 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $166.93 | 8 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $89,500 | 118 | Takeda Pharmaceuticals U.S.A., Inc. ($88,365) |
| 2023 | $45,412 | 100 | Takeda Pharmaceuticals U.S.A., Inc. ($43,820) |
| 2022 | $48,785 | 59 | Takeda Pharmaceuticals U.S.A., Inc. ($48,140) |
| 2021 | $38,329 | 37 | Takeda Pharmaceuticals U.S.A., Inc. ($37,902) |
| 2020 | $2,384 | 5 | Takeda Pharmaceuticals U.S.A., Inc. ($2,384) |
| 2018 | $240.04 | 11 | E.R. Squibb & Sons, L.L.C. ($142.22) |
| 2017 | $105.73 | 6 | E.R. Squibb & Sons, L.L.C. ($56.14) |
All Payment Transactions
336 individual payment records from CMS Open Payments — Page 1 of 14
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,616.65 | General |
| 12/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,193.33 | General |
| 12/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 11/13/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,193.33 | General |
| 11/13/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 10/30/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $24.39 | General |
| Category: Diabetes | ||||||
| 10/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | SYNJARDY (Drug) | Food and Beverage | In-kind items and services | $22.03 | General |
| Category: DIABETES | ||||||
| 10/10/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $16.76 | General |
| Category: Oncology | ||||||
| 10/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,193.33 | General |
| 10/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 10/03/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $15.13 | General |
| Category: Diabetes | ||||||
| 10/01/2024 | SHIELD THERAPEUTICS INC | ACCRUFER (Drug) | Food and Beverage | In-kind items and services | $18.61 | General |
| Category: Hematology | ||||||
| 09/23/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $22.34 | General |
| Category: Inflammation | ||||||
| 09/18/2024 | PFIZER INC. | ELIQUIS (Drug), NURTEC ODT | Food and Beverage | In-kind items and services | $21.45 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 09/18/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $14.09 | General |
| Category: GASTROENTEROLOGY | ||||||
| 09/12/2024 | Amgen Inc. | Otezla (Drug), Repatha | Food and Beverage | In-kind items and services | $13.91 | General |
| Category: Inflammation | ||||||
| 09/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 09/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 09/09/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $28.33 | General |
| 08/30/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $23.05 | General |
| 08/29/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.94 | General |
| Category: DIABETES | ||||||
| 08/26/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $24.14 | General |
| Category: NEUROSCIENCE | ||||||
| 08/19/2024 | Novartis Pharmaceuticals Corporation | LEQVIO (Drug) | Food and Beverage | In-kind items and services | $19.77 | General |
| Category: Cardiology/Vascular Diseases | ||||||
| 08/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
| 08/09/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $2,093.33 | General |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 425 | 714 | $187,686 | $58,390 |
| 2022 | 10 | 463 | 666 | $156,178 | $56,416 |
| 2021 | 5 | 220 | 263 | $43,217 | $21,634 |
All Medicare Procedures & Services
24 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 154 | 410 | $121,770 | $34,881 | 28.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 84 | 116 | $24,592 | $7,409 | 30.1% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2023 | 27 | 27 | $10,449 | $4,979 | 47.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 41 | 41 | $15,867 | $4,595 | 29.0% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 22 | 22 | $6,688 | $3,186 | 47.6% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 20 | 20 | $2,660 | $1,516 | 57.0% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 22 | 22 | $1,100 | $761.86 | 69.3% |
| 93922 | Ultrasound study of arm and leg arteries | Office | 2023 | 16 | 16 | $3,200 | $737.78 | 23.1% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 39 | 40 | $1,360 | $324.41 | 23.9% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 144 | 265 | $78,705 | $28,275 | 35.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 115 | 194 | $41,128 | $12,234 | 29.7% |
| G0438 | Annual wellness visit; includes a personalized prevention plan of service (pps), initial visit | Office | 2022 | 24 | 24 | $9,288 | $4,562 | 49.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 27 | 27 | $8,208 | $4,031 | 49.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 27 | 27 | $10,449 | $3,448 | 33.0% |
| 93922 | Ultrasound study of arm and leg arteries | Office | 2022 | 13 | 14 | $2,800 | $1,139 | 40.7% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 12 | 12 | $1,596 | $839.18 | 52.6% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 61 | 63 | $2,142 | $797.03 | 37.2% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 17 | 17 | $850.00 | $589.76 | 69.4% |
| G0444 | Annual depression screening, 15 minutes | Office | 2022 | 23 | 23 | $1,012 | $500.26 | 49.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 69 | 83 | $18,343 | $9,482 | 51.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 85 | 113 | $16,724 | $9,114 | 54.5% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 15 | 15 | $4,950 | $2,160 | 43.6% |
| G0444 | Annual depression screening, 15 minutes | Office | 2021 | 20 | 20 | $800.00 | $443.40 | 55.4% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 31 | 32 | $2,400 | $434.31 | 18.1% |
About Dr. Craig Washington, MD
Dr. Craig Washington, MD is a Internal Medicine healthcare provider based in Frederick, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/29/2017. The National Provider Identifier (NPI) number assigned to this provider is 1043731946.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Craig Washington, MD has received a total of $224,755 in payments from pharmaceutical and medical device companies, with $89,500 received in 2024. These payments were reported across 336 transactions from 33 companies. The most common payment nature is "Consulting Fee" ($217,954).
As a Medicare-enrolled provider, Washington has provided services to 1,108 Medicare beneficiaries, totaling 1,643 services with total Medicare billing of $136,441. Data is available for 3 years (2021–2023), covering 24 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties General Practice
- Location Frederick, MD
- Active Since 06/29/2017
- Last Updated 06/11/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1043731946
Products in Payments
- ELIQUIS (Drug) $298.43
- MOUNJARO (Drug) $289.21
- Ozempic (Drug) $198.09
- UBRELVY (Drug) $177.43
- Otezla (Drug) $174.64
- XARELTO (Drug) $166.93
- Rybelsus (Drug) $162.34
- Cologuard Collection Kit (Device) $159.26
- PREVNAR 20 (Biological) $145.98
- Kerendia (Drug) $145.25
- Repatha (Biological) $137.22
- QULIPTA (Drug) $133.18
- RYBELSUS (Drug) $125.60
- NURTEC ODT (Drug) $121.15
- FARXIGA (Drug) $92.26
- INTELLIS ADAPTIVESTIM (Device) $90.40
- ClosureFast (Device) $84.94
- ACCRUFER (Drug) $76.54
- JARDIANCE (Drug) $73.55
- TRELEGY ELLIPTA (Drug) $72.28
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Frederick
Rohan Rengen, D.o, D.O
Internal Medicine — Payments: $38,295
Sibte Kazmi, Md, MD
Internal Medicine — Payments: $14,311
Mouhamad Bazzi, Md, MD
Internal Medicine — Payments: $14,055
Dr. Syed Haque, M.d, M.D
Internal Medicine — Payments: $13,568
Daniel Daniels, M.d, M.D
Internal Medicine — Payments: $11,052
Anish Desai, M.d, M.D
Internal Medicine — Payments: $10,584